Poplar Forest Capital Lowers stake in Quest Diagnostics Inc (DGX)

Quest Diagnostics Inc (DGX) : Poplar Forest Capital reduced its stake in Quest Diagnostics Inc by 2.87% during the most recent quarter end. The investment management company now holds a total of 667,081 shares of Quest Diagnostics Inc which is valued at $50.7 Million after selling 19,710 shares in Quest Diagnostics Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.Quest Diagnostics Inc makes up approximately 4.39% of Poplar Forest Capital’s portfolio.

Other Hedge Funds, Including , Auxier Asset Management reduced its stake in DGX by selling 315 shares or 0.45% in the most recent quarter. The Hedge Fund company now holds 69,955 shares of DGX which is valued at $5.3 Million. Quest Diagnostics Inc makes up approx 1.26% of Auxier Asset Management’s portfolio.Her Majesty The Queen In Right Of The Province Of Alberta… reduced its stake in DGX by selling 101,540 shares or 66.57% in the most recent quarter. The Hedge Fund company now holds 50,990 shares of DGX which is valued at $3.9 Million. Quest Diagnostics Inc makes up approx 0.06% of Her Majesty The Queen In Right Of The Province Of Alberta…’s portfolio.Bronfman E.l. Rothschild reduced its stake in DGX by selling 292 shares or 57.94% in the most recent quarter. The Hedge Fund company now holds 212 shares of DGX which is valued at $16,065.Mitsubishi Ufj Kokusai Asset Management Ltd. boosted its stake in DGX in the latest quarter, The investment management firm added 1,827 additional shares and now holds a total of 20,900 shares of Quest Diagnostics Inc which is valued at $1.6 Million. Quest Diagnostics Inc makes up approx 0.04% of Mitsubishi Ufj Kokusai Asset Management Ltd.’s portfolio.

Quest Diagnostics Inc closed down -0.25 points or -0.32% at $77.37 with 12,03,068 shares getting traded on Wednesday. Post opening the session at $77.68, the shares hit an intraday low of $77.09 and an intraday high of $78.1 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Quest Diagnostics Inc reported $1.12 EPS for the quarter, based on the information available during the earnings call on Apr 21, 2016. Analyst had a consensus estimate of $1.12. The company had revenue of $1863.00 million for the quarter, compared to analysts expectations of $1823.36 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.05 EPS.

Investors should note that on May 18, 2016, Quest Diagnostics Inc announced a cash dividend of $0.4000. The company’s management has announced Jul 1, 2016 as the ex-dividend date and fixed the record date on Jul 6, 2016. The payable date has been fixed on Jul 20, 2016.

Many Wall Street Analysts have commented on Quest Diagnostics Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 76 from a previous price target of $70 .Company shares were Reiterated by Barclays on Apr 22, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $72 .Company shares were Reiterated by Mizuho on Apr 21, 2016 to “Buy”, Firm has raised the Price Target to $ 84 from a previous price target of $75 .

Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Company’s other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.

Leave a Reply

Quest Diagnostics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Quest Diagnostics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.